A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, Pharmacodynamics and Preliminary Anti-tumor Activity of ABO2102 in Participants With KRAS Mutant Solid Tumors
Latest Information Update: 11 Mar 2026
At a glance
- Drugs ABO 2102 (Primary) ; Sintilimab (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Suzhou Abogen Biosciences
Most Recent Events
- 11 Mar 2026 New trial record